Biotech Values

[dewophile]

I'm not sure where that poster is getting their numbers. The paper has multiple dosing scheduled in patients both on and off nuke therapy at entry. I would focus on the high dose arm which is being moved into phase 3, and if you want to compare to ABUS then only those on Nukes at study entry. The paper only gives the total who achived functional cure and then among those with baseline levels <3k. You have to go to the supplement to get the curves of paitnets <200 and then between 200-1k at baseline. There were only 19 patients on NA therapy and 11 off NA therapy total. so I have no idea where the poster is getting the N=59 for those 1k and under.
Remember ABUS requires 6 months of interferon, which is harsh. So even if efficacy ends up close there is no comparison on tolerability.